

# Latvia

Population (in millions) (2011)	<b>2.2</b>
Country classification (2012)	<b>Upper-middle-income</b>
Gross national income per capita (PPP int \$) (2011)	<b>\$17 700</b>
Total health expenditure as % of GDP (2010)	<b>6.68%</b>
Per capita total health expenditure (PPP int \$) (2010)	<b>\$1092.52</b>
Per capita government health expenditure (PPP int \$) (2010)	<b>\$667.99</b>
Life expectancy at birth (in years) (2009)	<b>72</b>
Human Development Index (2011)	<b>0.857</b>
Median age (in years) (2010)	<b>40</b>
Total fertility rate per woman (2010)	<b>1.5</b>

The Government of Latvia reports as follows.

## National coordination

There is no written national strategy or plan that focuses exclusively or primarily on the prevention and control of viral hepatitis.

There is no designated governmental unit/department responsible solely for coordinating and/or carrying out viral hepatitis-related activities. It is not known how many people work full-time on hepatitis-related activities in all government agencies/bodies.

The government has a viral hepatitis prevention and control programme that includes activities targeting the following specific populations: health-care workers (including health-care waste handlers), people who inject drugs, infants, adolescents, patients on dialysis and blood donors.

## Awareness-raising and partnerships

The government held events for World Hepatitis Day 2012, but has not funded other viral hepatitis public awareness campaigns since January 2011.

The government collaborates with the following in-country civil society groups to develop and implement its viral hepatitis prevention and control programme: Association HIV Latvia and the Hepatitis Association.

## Evidence-based policy and data for action

There is routine surveillance for viral hepatitis. There is a national surveillance system for the following types of acute hepatitis: A, B, C and E, and for the following types of chronic hepatitis: B and C.

There are standard case definitions for hepatitis. Deaths, including from hepatitis, are reported to a central registry. Of hepatitis cases, 3% are reported as "undifferentiated" or "unclassified" hepatitis.

Liver cancer cases and cases with HIV/hepatitis coinfection are registered nationally.

The government publishes hepatitis disease reports monthly and annually.

Hepatitis outbreaks are required to be reported to the government and are further investigated. There is adequate laboratory capacity nationally to support investigation of viral hepatitis outbreaks and other surveillance activities.

It is not known whether there is a national public health research agenda for viral hepatitis. Viral hepatitis serosurveys are not conducted regularly. The most recent serosurvey was conducted in 2000 and targeted pregnant women, boarding school students and new members of the military.

## Prevention of transmission

There is no national policy on hepatitis A vaccination.

The government has established the goal of reducing hepatitis B among children by 2011–2012.

Information was not provided on the percentage of newborn infants in a given recent year who received the first dose of hepatitis B vaccine within 24 hours of birth. Nationally, 91% of one-year-olds (ages 12–23 months) in a given recent year received three doses of hepatitis B vaccine.

There is a national policy that specifically targets mother-to-child transmission of hepatitis B (Annex B).

There is a specific national strategy and/or policy/guidelines for preventing hepatitis B and hepatitis C infection in health-care settings. Health-care workers are vaccinated against hepatitis B prior to starting work that might put them at risk of exposure to blood.

There is a national policy on injection safety in health-care settings, which recommends single-use syringes for therapeutic injections. Single-use or auto-disable syringes, needles and cannulas are always available in all health-care facilities.

Official government estimates of the number and percentage of unnecessary injections administered annually in health-care settings are not known.

There is a national infection control policy for blood banks. All donated blood units

(including family donations) and blood products nationwide are screened for hepatitis B and hepatitis C.

There is no national policy relating to the prevention of viral hepatitis among people who inject drugs.

The government does not have guidelines that address how hepatitis A and hepatitis E can be prevented through food and water safety.

## Screening, care and treatment

Health professionals obtain the skills and competencies required to effectively care for people with viral hepatitis through schools for health professionals (pre-service education) and on-the-job training.

There are national clinical guidelines for the management of viral hepatitis, which include recommendations for cases with HIV coinfection. Information was not provided on whether there are national clinical guidelines for the management of HIV, which include recommendations for coinfection with viral hepatitis.

The government does not have national policies relating to screening and referral to care for hepatitis B or hepatitis C.

People testing for both hepatitis B and hepatitis C register by name; the names are kept confidential within the system. Hepatitis B and hepatitis C tests are not free of charge for all individuals, but they are free of charge at syringe exchange points for people who inject drugs. Hepatitis B and hepatitis C tests are not compulsory for members of any specific group.

Publicly funded treatment is available for people chronically infected with hepatitis B and hepatitis C. For people with chronic hepatitis B, public funding covers inpatient hospital treatment. For people with chronic hepatitis C, public funding covers 75% of all treatment costs. The amount spent by the government on such treatment for hepatitis B and hepatitis C is not known.

The following drugs for treating hepatitis B are on the national essential medicines list or subsidized by the government: interferon alpha and lamivudine. The following drugs for treating hepatitis C are on the national essential medicines list or subsidized by the government: interferon alpha, pegylated interferon and ribavirin.

The Government of Latvia welcomes assistance from WHO in one or more areas of viral hepatitis prevention and control (Annex C).